Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Persistence of epstein-barr virus in vivo

Trial Profile

Persistence of epstein-barr virus in vivo

Phase of Trial: Phase III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Epstein-Barr virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top